These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11133602)

  • 1. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients.
    Dietrich W; Braun S; Spannagl M; Richter JA
    Anesth Analg; 2001 Jan; 92(1):66-71. PubMed ID: 11133602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time.
    Shore-Lesserson L; Manspeizer HE; Bolastig M; Harrington D; Vela-Cantos F; DePerio M
    Anesth Analg; 2000 Apr; 90(4):813-8. PubMed ID: 10735781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass.
    Nicholson SC; Keeling DM; Sinclair ME; Evans RD
    Br J Anaesth; 2001 Dec; 87(6):844-7. PubMed ID: 11878684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass.
    Linden MD; Schneider M; Baker S; Erber WN
    J Cardiothorac Vasc Anesth; 2004 Apr; 18(2):131-5. PubMed ID: 15073698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT.
    Ichikawa J; Mori T; Kodaka M; Nishiyama K; Ozaki M; Komori M
    Perfusion; 2017 Sep; 32(6):474-480. PubMed ID: 28820035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of goal-directed therapy for the use of concentrated antithrombin for heparin resistance during cardiac surgery.
    Stammers AH; Francis SG; Miller R; Nostro A; Tesdahl EA; Mongero LB
    Perfusion; 2021 Mar; 36(2):171-182. PubMed ID: 32536326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
    Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
    Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplemental Antithrombin Is Effective in Achieving Adequate Anticoagulation in Infants and Children With an Inadequate Response to Heparin.
    Lopez M; Feng C; Vasilyeva O; Eaton MP
    J Cardiothorac Vasc Anesth; 2017 Jun; 31(3):896-900. PubMed ID: 28242144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adjusted Calculation Model of Reduced Heparin Doses in Cardiopulmonary Bypass Surgery in a Chinese Population.
    Zhang Y; Liu K; Li W; Xue Q; Hong J; Xu J; Wu L; Ji G; Sheng J; Wang Z
    J Cardiothorac Vasc Anesth; 2016 Oct; 30(5):1179-83. PubMed ID: 27475733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery.
    Jooste EH; Scholl R; Wu YH; Jaquiss RDB; Lodge AJ; Ames WA; Homi HM; Machovec KA; Greene NH; Donahue BS; Shah N; Benkwitz C
    J Cardiothorac Vasc Anesth; 2019 Feb; 33(2):396-402. PubMed ID: 30072263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin sensitivity test for patients requiring cardiopulmonary bypass.
    DeBois WJ; Liu J; Elmer B; Ebrahimi H; Voevidko L; Lee LY; Krieger KH; Isom WW; Girardi LN
    J Extra Corpor Technol; 2006 Dec; 38(4):307-9. PubMed ID: 17312901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
    Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.
    Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ
    Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.